S'abonner

Phytochemicals targeting lncRNAs: A novel direction for neuroprotection in neurological disorders - 29/04/23

Doi : 10.1016/j.biopha.2023.114692 
Hang Zhao a, 1, Lin Wang b, Lijuan Zhang c, , 2 , Hongyu Zhao b, , 2
a Department of Family Medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 
b Department of Emergency medicine, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 
c Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, PR China 

Correspondence to: Departments of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110000, Liaoning, PR China.Departments of Obstetrics and Gynecology, Shengjing Hospital of China Medical UniversityNo. 39 Huaxiang Road, Tiexi DistrictShenyangLiaoning110000PR China⁎⁎Correspondence to: Department of Emergency medicine, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Tiexi District, Shenyang 110000, Liaoning, PR China.Department of Emergency medicine, Shengjing Hospital of China Medical UniversityNo. 39 Huaxiang Road, Tiexi DistrictShenyangLiaoning110000PR China

Abstract

Neurological disorders with various etiologies impacting the nervous system are prevalent in clinical practice. Long non-coding RNA (lncRNA) molecules are functional RNA molecules exceeding 200 nucleotides in length that do not encode proteins, but participate in essential activities. Research indicates that lncRNAs may contribute to the pathogenesis of neurological disorders, and may be potential targets for their treatment. Phytochemicals in traditional Chinese herbal medicine (CHM) have been found to exert neuroprotective effects by targeting lncRNAs and regulating gene expression and various signaling pathways. We aim to establish the development status and neuroprotective mechanism of phytochemicals that target lncRNAs through a thorough literature review. A total of 369 articles were retrieved through manual and electronic searches of PubMed, Web of Science, Scopus and CNKI databases from inception to September 2022. The search utilized combinations of natural products, lncRNAs, neurological disorders, and neuroprotective effects as keywords. The included studies, a total of 31 preclinical trials, were critically reviewed to present the current situation and the progress in phytochemical-targeted lncRNAs in neuroprotection. Phytochemicals have demonstrated neuroprotective effects in preclinical studies of various neurological disorders by regulating lncRNAs. These disorders include arteriosclerotic ischemia-reperfusion injury, ischemic/hemorrhagic stroke, Alzheimer's disease, Parkinson's disease, glioma, peripheral nerve injury, post-stroke depression, and depression. Several phytochemicals exert neuroprotective roles through mechanisms such as anti-inflammatory, antioxidant, anti-apoptosis, autophagy regulation, and antagonism of Aβ-induced neurotoxicity. Some phytochemicals targeted lncRNAs and served a neuroprotective role by regulating microRNA and mRNA expression. The emergence of lncRNAs as pathological regulators provides a novel direction for the study of phytochemicals in CHM. Elucidating the mechanism of phytochemicals regulating lncRNAs will help to identify new therapeutic targets and promote their application in precision medicine.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

31 papers were reviewed to elucidate phytochemical-targeted lncRNAs in neuroprotection.
Phytochemicals could be a new candidate drug for treating neurological disorders.
Anti-inflammatory, anti-oxidative, anti-apoptotic effects are common mechanisms of phytochemicals regulate lncRNAs.

Le texte complet de cet article est disponible en PDF.

Abbreviations : AD, AoSMCs/HA-VSMCs, AS-IV, ATGL, BMDMs, BMECs, BMVEC, CHOP, EGFR, ELF5, EndMT, ERK, ERS, EZH2, FGF-2, GBM, GP, GPx, HFD, HIF-1α, HT22, HUVEC, ICAM‑1, ICH, IL, JNK, LDH, LDL, MCP‑1, MCAO, MDA, MPP+, MPTP, mTOR, NF-κB, NGR1, NLRP3, OGD, PCA, PCNA, PD, PPARγ, ROS, SNCA, SD, SOD, SYB, TGF-β, TH, TMP, TNF, VEGFA, VSMCs, ZNF217

Keywords : Neurological disorders, LncRNAs, Phytochemicals, Traditional Chinese herbal medicine, Pharmacology, Neuroprotection


Plan


© 2023  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 162

Article 114692- juin 2023 Retour au numéro
Article précédent Article précédent
  • Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
  • Da Qian, Jialu Li, Mingyao Huang, Qiuxia Cui, Xiaozhen Liu, Kailv Sun
| Article suivant Article suivant
  • Cell signaling pathways based on vitamin C and their application in cancer therapy
  • Dianfa Fan, Xiyu Liu, Zhen Shen, Pan Wu, Liping Zhong, Faquan Lin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.